Specialty Pharma Journal Specialty, Precision & Technology
SAN DIEGO, Dec. 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc., an innovator in predicting disease …
Tag Archives: targeted therapies
December, 2018
July, 2018
-
18 July
Sanofi and REVOLUTION Medicines Partner to Develop Targeted Therapies for Multiple Cancers
CAMBRIDGE, Mass. & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with non-small lung cancer and other types of cancer carrying certain mutations. This collaboration builds on precision oncology discoveries …
December, 2017
-
15 December
Statement from FDA Commissioner Gottlieb on New FDA Efforts to Support More Efficient Development of Targeted Therapies
SILVER SPRING, Md., Dec. 15, 2017 /PRNewswire-USNewswire/ — In recent years, the medical community has experienced a shift in the way health care is practiced. Rather than focusing solely on how to treat an overall disease type, medical innovators are now exploring how to tailor treatments that target unique characteristics …
May, 2015
-
5 May
IMS Reports Global Spending on Cancer Drugs Reaches $100 Billion in 2014
While the share of total medicine spending on oncologics increased only modestly, the total global spending on oncology medicines reached $100 billion in 2014, according to a new report from IMS Institute for Healthcare Informatics. The Global Oncology Trend Report showed that global spending on cancer drugs, including therapeutic treatments …
April, 2015
-
23 April
MedImmune and Juno Collaborate to Study Cancer Immunotherapy Combo
AstraZeneca’s biologics research and development arm, MedImmune, is pairing its investigational PD-L1 checkpoint inhibitor with Juno Therapeutics’ investigational targeted CAR T cell candidates for potential new therapies. The companies said that they have entered into a new collaboration to conduct combination clinical trials in immuno-oncology with Juno’s CD19-directed chimeric antigen …
-
17 April
AstraZeneca’s Investigational Lung Cancer Drug Delays Disease Progression by more than a Year
AstraZeneca’s investigational lung cancer drug delayed disease progression by more than a year in a mid-stage study. Today, the company announced the latest data from the ongoing AURA study evaluating AZD9291 in patients with advanced epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC), who also have …
-
16 April
Study Finds Inaccuracies with Tumor-Only Gene Sequencing
New cancer tests that only sequence alterations in a patient’s tumor could lead to a significant number of patients receiving inappropriate treatment, a new study suggests. A new study, published in Science Translational Medicine, conducted by scientists from Personal Genome Diagnostics, Inc. (PGDx) and Johns Hopkins Kimmel Cancer Center, found …
-
14 April
Roche’s Ventana Enters Deal to Develop Companion Diagnostic Test for Astellas Cancer Compound
Roche’s Ventana Medical Systems has inked a deal with Astellas Pharma aimed at developing new diagnostic tests for targeted cancer treatments. The cancer diagnostics company announced that it has entered into master collaboration agreement with Astellas Pharma to develop novel automated tissue diagnostics in support of therapeutic compounds in development. …
March, 2015
-
23 March
ImmunoGen Licenses ADC Technology to Takeda for Development of Cancer Drugs
Oncology biotech ImmunoGen, Inc. announced that it has entered into a $440 million antibody-drug conjugate (ADC) licensing deal with Takeda Pharmaceutical Company Limited. Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets. Under the deal, ImmunoGen …
-
19 March
Ignyta Advances its Precision Oncology Vision with its Acquisition of Four Targeted Cancer Programs from Teva
Precision oncology biotech Ignyta has acquired worldwide rights and assets relating to four targeted oncology development programs from Teva Pharmaceutical Industries. The companies announced that Ignyta will acquire four oncology assets from Teva in exchange for 1.5 million shares, or six percent of Ignyta’s common stock. Concurrently, Ignyta has entered …